The EPS beat and cash runway through 2028 are positive, but the revenue decline and lack of near-term catalysts (data not expected until 2H 2027) limit upside. Monitor upcoming investor events (Guggenheim Nov 9, Jefferies Nov 17) for any updates on trial enrollment or partnership milestones.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $2.95entry
- T+1 · 11d ago +5.08%α +4.77% · $3.10
- T+5 · 5d ago −6.10%α −9.39% · $2.77
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
C4 Therapeutics reported Q3 2026 revenue of $8.5M (in line with $8.5M consensus) and a net loss per share of -$0.16, beating the -$0.21 consensus estimate. The company highlighted progress in its cemsidomide clinical program with Phase 2 MOMENTUM trial enrollment on track for Q1 2027 completion and initial ORR data expected in 2H 2027.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $8.5M vs $11.2M in Q3 2025, down 24% YoY
- Q3 2026 net loss per share -$0.16 vs -$0.44 in Q3 2025
- EPS beat consensus of -$0.21 by 23.8%
- Cash, cash equivalents and marketable securities $274.7M as of Sep 30, 2026, expected to fund operations to end of 2028
- Phase 2 MOMENTUM trial enrollment on track to complete in Q1 2027; initial ORR data expected in 2H 2027
- Phase 1b trial of cemsidomide with elranatamab advancing; data from all cohorts expected mid-2027
Financial Impact
Revenue decline of $2.7M YoY (24%) due to conclusion of certain collaboration activities; net loss improved by $10.4M YoY driven by lower operating expenses and no impairment charge
Risk Factors
- Revenue decline of 24% YoY due to reduced collaboration activities
- Clinical-stage company with no approved products; all value depends on cemsidomide trial outcomes
- Key data readouts not expected until mid-2027 and 2H 2027, creating a long catalyst gap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396251 |
Track record
19 reports on CCCC
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
- Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
- Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
- Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers